Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

Over the past decade, scientists have developed reversal agents for specific anticoagulants, including idarucizumab for ...

Dabigatran and apixaban are approved to reduce the risk of stroke and thrombosis in patients with nonvalvular atrial fibrillation. Rivaroxaban, the first Factor Xa inhibitor, is approved for ...